Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line

By Qi Hui wei   Shen Zan   Fan Li hong  

Experimental and Therapeutic Medicine, Vol. 2, Iss. 6, 2011-11 ,pp. : 1091-1095

Spandidos Publications

Access to resources Recommend Favorite